Physician profile
Matthew James Baker
NPI 1154372167
$1,428,854.53
in general payments reported to CMS, 2019-2025
70 companies · $288K in 2025
The $288K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $258K · 2020: $147K · 2021: $144K · 2022: $197K · 2023: $179K · 2024: $216K · 2025: $288K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $553K · Travel and Lodging: $60K · Consulting Fee: $42K · Food and Beverage: $28K · Education: $64.99 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $553,494.65 |
| Travel and Lodging | $59,644.69 |
| Consulting Fee | $41,597.00 |
| Food and Beverage | $28,122.87 |
| Education | $64.99 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $233,362.15 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Alexion Pharmaceuticals, INC. | $228,405.99 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $205,201.45 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $101,014.48 | 2020-2025 | Zeposia |
| Abbvie INC. | $99,855.80 | 2020-2025 | Qulipta, Ubrelvy, Duopa |
| Otsuka America Pharmaceutical, INC. | $90,560.38 | 2023-2024 | Nuedexta, Rexulti |
| Genzyme Corporation | $90,344.23 | 2019-2025 | |
| Tg Therapeutics, INC. | $81,458.34 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $66,282.61 | 2020-2025 | Acthar |
| Genentech USA, INC. | $52,255.14 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Avanir Pharmaceuticals, INC. | $49,291.88 | 2019-2022 | |
| Celgene Corporation | $30,426.96 | 2019-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $22,052.76 | 2019-2024 | Austedo Xr, Austedo |
| Allergan, INC. | $20,241.11 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $11,158.01 | 2021 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,256.09 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $8,710.59 | 2019 | |
| Argenx US, INC. | $6,983.36 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech, INC. | $3,588.83 | 2021-2024 | Ocrevus |
| Ares Trading Sa | $3,127.50 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,958.65 | 2022 | |
| Horizon Therapeutics Plc | $1,555.27 | 2021-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $1,483.82 | 2023-2024 | Onpattro |
| Banner Life Sciences, LLC | $944.56 | 2021-2022 | |
| Ucb, INC. | $943.98 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Modernatx, INC. | $849.16 | 2024 | |
| Amgen INC. | $595.83 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $489.42 | 2019-2025 | Nuplazid |
| Eisai INC. | $475.87 | 2021-2025 | |
| Lilly USA, LLC | $417.22 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Ge Healthcare | $365.25 | 2020-2025 | |
| Lundbeck LLC | $293.70 | 2023-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $293.45 | 2021-2025 | Xcopri |
| Acorda Therapeutics, INC | $249.56 | 2019-2023 | Ampyra, Inbrija |
| Pfizer INC. | $237.53 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $222.86 | 2019-2022 | |
| Neurelis, INC. | $208.45 | 2022-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $168.81 | 2023 | Aptiom |
| Janssen Pharmaceuticals, INC | $143.25 | 2022 | |
| Neurocrine Biosciences, INC. | $132.47 | 2020-2025 | Ingrezza, Ongentys |
| Vanda Pharmaceuticals INC. | $105.58 | 2024-2025 | Ponvory |
| Kyowa Kirin, INC. | $100.99 | 2021-2024 | Nourianz |
| Harmony Biosciences LLC | $97.41 | 2020-2023 | Wakix |
| Amneal Pharmaceuticals LLC | $84.84 | 2020-2025 | Crexont, Rytary |
| Mdd US Operations, LLC | $81.54 | 2021-2024 | Gocovri |
| Cvrx, INC. | $79.03 | 2023 | Barostim Neo System |
| Adamas Pharmaceuticals, INC. | $70.86 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $69.65 | 2023-2024 | Ztlido |
| Greenwich Biosciences, INC. | $62.78 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $54.89 | 2023-2024 | Xeomin |
| Catalyst Pharmaceuticals, INC. | $44.69 | 2021-2022 | |
| Tanabe Pharma America, INC. | $43.75 | 2019-2020 | |
| Octapharma USA, INC. | $37.95 | 2021-2025 | Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $34.72 | 2022 | |
| Xeris Pharmaceuticals, INC. | $33.04 | 2025 | Keveyis |
| Sanofi-Aventis U.S. LLC | $31.70 | 2019-2021 | |
| Novocure INC. | $28.66 | 2025 | Optune Gio |
| Merz North America, INC. | $23.81 | 2019 | |
| Grifols USA, LLC | $22.64 | 2025 | Gamunex-C |
| Astrazeneca Pharmaceuticals LP | $21.52 | 2024 | Andexxa |
| Avion Pharmaceuticals | $20.15 | 2022 | |
| Medtronic, INC. | $18.53 | 2025 | Percept PC Brainsense |
| Janssen Biotech, INC. | $17.56 | 2025 | |
| Medtronic USA, INC. | $17.06 | 2019 | |
| Portola Pharmaceuticals, LLC | $16.11 | 2019 | |
| Almatica Pharma LLC | $14.73 | 2022 | |
| Impel Pharmaceuticals INC. | $13.57 | 2023 | Trudhesa |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,475.27 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.